Mesenchymal stem cells for systemic therapy: shotgun approach or magic bullets?

Area of Science:

• Cell biology
• Regenerative medicine
• Nanotechnology

Background:

• Mesenchymal stem/stromal cells (MSCs) exhibit heterogeneity and lack defining markers, yet attract significant translational research.
• Evidence suggests MSCs primarily exert therapeutic effects through paracrine mediators and exosomes, rather than direct differentiation.
• Challenges remain in achieving long-term MSC engraftment and controlling their behavior in target niches.

Purpose of the Study:

• To review the current understanding of MSC mechanisms of action.
• To explore the potential of exosome-based therapies and nanoparticle delivery systems.
• To discuss the clinical utility of perinatal MSCs.

Main Methods:

• Literature review of MSC research, focusing on paracrine effects, exosomes, and nanoparticle applications.
• Analysis of challenges in MSC engraftment and niche manipulation.
• Evaluation of perinatal MSCs for allogeneic clinical trials.

Main Results:

• MSC therapeutic potential is increasingly attributed to paracrine factors and exosomes.
• Nanoparticle technology enhances MSCs for targeted drug delivery.
• Systemic cell-free exosome delivery shows promise for acute injuries, potentially replacing cell transplantation.
• Perinatal MSCs are increasingly used in clinical trials due to favorable collection and developmental properties.

Conclusions:

• MSC-based therapies are evolving, with a shift towards understanding and utilizing their paracrine and exosome-mediated effects.
• Exosome delivery offers a promising cell-free alternative for regenerative medicine and acute injury treatment.
• Perinatal MSCs represent a valuable source for allogeneic cell-based therapies.